Literature DB >> 9930331

Inflammatory responses following direct injection of plasmid DNA into skeletal muscle.

J M McMahon1, K E Wells, J E Bamfo, M A Cartwright, D J Wells.   

Abstract

Transfer of genes by injection of plasmid DNA into skeletal muscle has a wide variety of applications ranging from treatment of neuromuscular disorders to genetic vaccination. We examined each component involved in the intramuscular injection of plasmid DNA in terms of the induction of inflammatory responses. The insertion of a needle and the injection of a relatively large volume of saline caused very little muscle damage except in rare cases. In contrast, barium chloride-induced regeneration of muscle, injection of lipopolysaccharide, plasmid backbone or plasmid expressing a neo-antigen (beta-galactosidase) all generated widespread inflammation of injected muscle, with mononuclear infiltrate, comprised largely of macrophages and with both CD4+ and CD8+ T lymphocytes, present. Such inflammation may hamper clinical application of this technology and may encourage undesirable immune responses in gene therapy trials. Inflammation was not greatly reduced by CD4- or CD8-depleting antibodies, suggesting this initial inflammation did not involve T cells, but methylation of plasmid DNA before injection substantially lessened the inflammatory response and resulted in longer term expression of the transgene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9930331     DOI: 10.1038/sj.gt.3300718

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  15 in total

1.  The safety and longevity of DNA vaccines for fish.

Authors:  T Kanellos; I D Sylvester; A G Ambali; C R Howard; P H Russell
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

Review 2.  Rational vector design for efficient non-viral gene delivery: challenges facing the use of plasmid DNA.

Authors:  Juergen Mairhofer; Reingard Grabherr
Journal:  Mol Biotechnol       Date:  2008-06       Impact factor: 2.695

3.  Intradermal active full-length DNA Aβ42 immunization via electroporation leads to high anti-Aβ antibody levels in wild-type mice.

Authors:  Roger N Rosenberg; Min Fu; Doris Lambracht-Washington
Journal:  J Neuroimmunol       Date:  2018-06-11       Impact factor: 3.478

4.  TLR9 and IRF3 cooperate to induce a systemic inflammatory response in mice injected with liposome:DNA.

Authors:  Wendy E Walker; Carmen J Booth; Daniel R Goldstein
Journal:  Mol Ther       Date:  2010-02-09       Impact factor: 11.454

5.  Immunogenicity of intrathecal plasmid gene delivery: cytokine release and effects on transgene expression.

Authors:  Travis S Hughes; Stephen J Langer; Salla I Virtanen; Raymond A Chavez; Linda R Watkins; Erin D Milligan; Leslie A Leinwand
Journal:  J Gene Med       Date:  2009-09       Impact factor: 4.565

6.  Efficient expression of vascular endothelial growth factor using minicircle DNA for angiogenic gene therapy.

Authors:  Chien-Wen Chang; Lane V Christensen; Minhyung Lee; Sung Wan Kim
Journal:  J Control Release       Date:  2007-10-24       Impact factor: 9.776

Review 7.  Molecular-genetic imaging of cancer.

Authors:  Il Minn; Mitchell E Menezes; Siddik Sarkar; Keerthi Yarlagadda; Swadesh K Das; Luni Emdad; Devanand Sarkar; Paul B Fisher; Martin G Pomper
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

8.  Induction of tumor-specific immune response by gene transfer of Hsp70-cell-penetrating peptide fusion protein to tumors in mice.

Authors:  Makiya Nishikawa; Takayuki Otsuki; Atsushi Ota; Xin Guan; Seiji Takemoto; Yuki Takahashi; Yoshinobu Takakura
Journal:  Mol Ther       Date:  2009-09-01       Impact factor: 11.454

9.  Electroporation-mediated transfer of plasmids to the lung results in reduced TLR9 signaling and inflammation.

Authors:  R Zhou; J E Norton; N Zhang; D A Dean
Journal:  Gene Ther       Date:  2007-03-08       Impact factor: 5.250

10.  Plasmid injection and application of electric pulses alter endogenous mRNA and protein expression in B16.F10 mouse melanomas.

Authors:  L C Heller; Y L Cruz; B Ferraro; H Yang; R Heller
Journal:  Cancer Gene Ther       Date:  2010-08-13       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.